Combined organ and hematopoietic cells for transplantation tolerance of grafts

Patent metadata

Field	Value
Publication number	US-12303532-B2
Application number	US-202217872741-A
Country	US
Kind code	B2
Filing date	Jul 25, 2022
Priority date	Feb 26, 2013
Publication date	May 20, 2025
Grant date	May 20, 2025

Abstract

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

First claim

What is claimed is:

1. A method for manufacturing a cellular product, the method comprising:
receiving an apheresis product from a donor comprising CD34 + cells and CD3 + cells;
processing the apheresis product to produce a cellular product comprising an effective amount of CD34 + cells/kilogram recipient weight in a cryopreservation solution; an effective amount of at least 1×10 7 CD3 + T cells/kilogram recipient weight in the cryopreservation solution; and a cell type in the cryopreservation solution that facilitates engraftment of the hematopoietic stem cells in a bone marrow of a recipient of a solid organ transplant; and
analyzing the cellular product for one or more quality criteria.

2. The method of claim 1 , wherein if the one or more quality criteria are satisfied, cryopreserving the cellular product.

3. The method of claim 2 , further comprising shipping the cryopreserved cellular product to a location where the solid organ transplant is occurring.

4. The method of claim 1 , wherein the one or more quality criteria are at least one quality criteria selected from the group consisting of cell count, viability, sterility, and a combination thereof.

5. The method of claim 4 , wherein the one or more quality criteria is cell count of the hematopoietic stem cells, and an amount of the hematopoietic stem cells in the cellular composition is adjusted based on results of the cell count.

6. The method of claim 1 , wherein the apheresis product is from a donor that is HLA matched to the recipient.

7. The method of claim 1 , wherein the apheresis product is from a donor that is HLA mis-matched to the recipient.

8. The method of claim 1 , wherein the cellular product is formulated for infusion into the recipient.

9. The method of claim 1 , wherein the cell type that facilitates engraftment of the hematopoietic stem cells in the bone marrow of the recipient is a complementary cell type.

10. The method of claim 9 , wherein the complementary cell type is one or more type of endothelial cell.

11. The method of claim 1 , wherein receiving the apheresis product from the donor comprises sampling the apheresis product during collection.

12. The method of claim 11 , wherein sampling comprises measuring the white blood cell count and/or platelet count during collection.

13. The method of claim 12 , further comprising adjusting the rate of collection based on the measured white blood cell count and/or platelet count during collection.

14. The method of claim 1 , wherein the cryopreservation medium contains dimethylsulfoxide (DMSO).

15. The method of claim 1 , wherein the effective amount of CD34 + cells/kilogram recipient weight comprises at least 1×10 7 purified CD34 + cells/kilogram recipient weight.

16. The method of claim 1 , wherein the effective amount of CD3 + T cells/kilogram recipient weight comprises at least 4×10 7 CD3 + T cells/kilogram recipient weight.

17. The method of claim 1 , wherein the effective amount of CD3+ T cells/kilogram recipient weight comprises about 5×10 7 CD3 + T cells/kilogram recipient weight.

18. The method of claim 1 , wherein a donor of the solid organ and the donor of the CD34 + cells and the CD3 + cell are the same.

19. The method of claim 1 , wherein the CD34+ cells and the CD3+ cells are from a single apheresis product.

Assignees

• Univ Leland Stanford Junior

Inventors

• Strober Samuel
• Lowsky Robert

Classifications

• A61K2035/122

  for inducing tolerance or supression of immune responses · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title

• A61K2039/515

  Animal cells · CPC title